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Summary
Background.  —  The  classiﬁcation  of  atrial  ﬁbrillation  as  paroxysmal  or  persistent  (PsAF)  is  clin-
ically useful,  but  does  not  accurately  reﬂect  the  underlying  pathophysiology  and  is  therefore  a
suboptimal  guide  to  selection  of  ablation  strategy.
Aim. —  To  determine  if  additional  substrate  ablation  is  beneﬁcial  for  a  subset  of  patients  with
PsAF, in  whom  long  periods  of  sinus  rhythm  (SR)  can  be  maintained.
Methods.  —  We  included  patients  presenting  with  PsAF  in  whom  continuous  periods  of
SR >  3  months  were  documented.  All  patients  were  in  SR  on  the  day  of  the  procedure.  Electrical
pulmonary  vein  isolation  (PVI)  was  performed  in  all  patients.  Additional  electrogram  (EGM)-
guided ablation  was  left  to  the  discretion  of  the  operator.  Patient  characteristics  and  follow-up
were analysed  with  respect  to  presence  or  absence  of  additional  EGM-guided  ablation.
Results. —  Sixty-ﬁve  patients  (mean  age  60.1  ±  8.9  years;  81.5%  men)  met  the  inclusion  criteria.
EGM-guided  ablation  was  performed  in  32  (49%)  patients.  Patients  with  and  without  EGM-guided
ablation  had  similar  baseline  characteristics.  Absence  of  EGM-guided  ablation  was  one  of  the
independent  predictors  for  arrhythmia  recurrences  after  the  index  procedure  (hazard  ratio
0.24; conﬁdence  interval  0.12—0.47).  After  a  median  follow-up  of  18  ±  10  months,  the  number  of
procedures required  was  signiﬁcantly  higher  in  the  ‘PVI-only’  group  (2.24  ±  0.75  vs.  1.84  ±  0.81;
P =  0.04)  to  achieve  a  similar  success  rate  (84%  vs.  81%;  P  =  0.833).
Conclusion.  —  The  addition  of  EGM-guided  ablation  requires  fewer  procedures  to  achieve  similar
clinical efﬁcacy  in  mid-term  follow-up  compared  with  a  PVI-only  strategy  in  patients  with  PsAF
presenting  for  ablation  in  SR.
©  2013  Published  by  Elsevier  Masson  SAS.
MOTS  CLÉS
Fibrillation  atriale
persistante  ;
Ablation  de
ﬁbrillation  atriale  ;
Isolation  des  veines
pulmonaires  ;
Ablation  de  substrat
atrial
Résumé
Contexte.  —  La  classiﬁcation  de  la  ﬁbrillation  atriale  (FA)  en  FA  paroxystique  ou  persistante  est
utile sur  le  plan  clinique  mais  ne  reﬂète  que  partiellement  la  physiopathologie  de  cette  maladie
et n’est  pas  optimale  pour  adapter  la  stratégie  d’ablation  de  FA.
Objectifs.  —  Pour  déterminer  si  une  ablation  complémentaire  du  substrat  atrial  est  bénéﬁque
chez les  patients  souffrant  de  FA  persistante  chez  lesquels  des  périodes  de  maintien  en  rythme
sinusal (RS)  sont  observées.
Méthodes.  —  Nous  avons  inclus  des  patients  souffrant  de  FA  persistante  et  pour  lesquels  des
périodes  continues  en  RS  de  plus  de  trois  mois  ont  été  observées.  De  plus,  tous  ces  patients
étaient en  RS  le  jour  de  la  procédure  d’ablation  de  FA.  Tous  les  patients  ont  bénéﬁcié  d’une
isolation  des  veines  pulmonaires  (IVP).  Une  ablation  complémentaire  de  potentiels  fragmentés
en FA  a  été  réalisée  selon  l’avis  de  l’opérateur.  Les  caractéristiques  des  patients  et  leur  suivi
étaient analysés  selon  la  réalisation  d’ablation  de  potentiels  fragmentés  en  plus  ou  non.
Résultats.  —  Soixante-cinq  patients  (âge  :  60,1  ±  8,9  ans,  homme  :  81,5  %)  ont  rempli  les  critères
d’inclusion  de  l’étude.  La  réalisation  d’ablation  complémentaire  de  potentiels  fragmentés  a
été réalisée  chez  32  (49  %)  patients.  Les  patients  ayant  eu  ou  non  une  ablation  complémentaire
avaient les  mêmes  caractéristiques  de  base.  L’absence  de  réalisation  d’ablation  complémen-
taire était  un  facteur  indépendant  de  récidives  d’arythmie  après  la  première  procédure  (hazard
ratio 0,24  ;  intervalle  de  conﬁance  0,12—0,47).  Après  un  suivi  median  de  18  ±  10  mois,  le  nom-
bre total  de  procédures  d’ablation  était  plus  élevé  chez  les  patients  ayant  eu  seulement  l’IVP
par rapport  aux  patients  ayant  eu  en  plus  une  ablation  complémentaire  de  substrat  atrial
(2,24 ±  0,75  vs  1,84  ±  0,81  ;  p  =  0,04)  pour  aboutir  à  un  taux  de  succès  similaire  (84  %  vs  81  %  ;
p =  0,833).
Conclusion.  —  La  réalisation  d’une  ablation  complémentaire  de  substrat  atrial  en  plus  de  l’IVP
lors de  la  première  intervention  d’ablation  de  FA  chez  les  patients  souffrant  de  FA  persistante
en RS  le  jour  de  l’intervention  permet  de  diminuer  le  nombre  total  de  procédures  nécessaires
pour aboutir  à  un  taux  de  succès  similaire.
© 2013  Publié  par  Elsevier  Masson  SAS.
B
T
p
t
mackgroundhe  natural  course  of  atrial  ﬁbrillation  (AF)  progresses  from
aroxysmal  (PAF),  which  by  deﬁnition  is  self-terminating,
o  persistent  (PsAF),  which  requires  medical  intervention  to
e
P
taintain  sinus  rhythm  (SR)  [1].  Catheter  ablation  of  AF  has
merged  as  a  promising  treatment  strategy  for  both  PAF  and
sAF  [2—8].
Paroxysmal  AF  results  from  pulmonary  vein  ectopies  in
he  majority  of  cases,  so  pulmonary  vein  isolation  (PVI)  alone
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has  emerged  as  the  ablation  strategy  of  choice  [9].  In  PsAF,
although  the  pulmonary  veins  have  an  important  arrhyth-
mogenic  role,  the  altered  atrial  substrate  contributes  to
sustained  arrhythmia  [10].  Recognition  of  the  need  for
atrial  substrate  modiﬁcation  has  led  operators  to  propose
interventional  strategies,  including  linear  and  electrogram
(EGM)-guided  ablation.  Nevertheless,  the  ideal  ablation
strategy  for  PsAF  remains  controversial  [11]  and,  when  com-
pared  with  ablation  for  PAF,  the  results  are  less  reproducible
between  centres  and  patients  require  more  procedures  to
maintain  SR  [12].
The  classiﬁcation  of  AF  into  PAF  and  PsAF  is  simplistic
and,  although  clinically  useful,  there  is  a  growing  body  of
data  to  argue  that  it  does  not  accurately  reﬂect  the  under-
lying  pathophysiology.  Furthermore,  it  is  clear  that  there  are
patients  with  PsAF  in  whom  catheter  ablation  is  an  inappro-
priate  treatment,  with  increasing  emphasis  being  placed  on
improved  patient  selection  and  earlier  intervention  to  pre-
vent  disease  progression.  We  sought  to  examine  a  cohort  of
PsAF  patients  in  whom  the  use  of  direct  current  cardiover-
sion  (DCCV)  with  or  without  pharmacological  support  leads
to  prolonged  periods  of  SR.  We  hypothesized  that  this  group
represents  an  early  pathophysiological  stage  of  PsAF  and
that  additional  substrate  ablation  may  therefore  be  neces-
sary  to  achieve  a  good  clinical  outcome.
Methods
Study population
A  cohort  of  consecutive  patients  referred  to  St  Thomas’
Hospital  (London,  UK)  and  the  Henri-Mondor  Hospital
(Creteil,  France)  for  a  ﬁrst  PsAF  ablation  procedure  between
January  2009  and  March  2011,  with  ≥  3  months  of  SR
being  maintained  between  serial  DCCVs  within  the  year
preceding  the  index  procedure,  were  retrospectively  anal-
ysed.  All  patients  were  in  SR  on  the  day  of  the  ﬁrst
ablation  procedure.  The  endpoint  of  the  study  was  recur-
rence  of  any  atrial  tachyarrhythmia  lasting  >  30  seconds.
After  the  ablation  procedure,  a  3-month  blanking  period
was  observed,  during  which  arrhythmia  recurrences  were
treated  conservatively  by  rate  control  or  cardioversion
and/or  antiarrhythmic  drug  therapy.  All  recurrences  after
the  blanking  period  were  considered  as  procedural  fail-
ures.  Patient  characteristics  and  follow-up  were  analysed
with  respect  to  presence  and  absence  of  additional  EGM-
guided  ablation.  This  study,  which  is  in  compliance  with
the  ethical  principles  formulated  in  the  Declaration  of
Helsinki,  was  approved  by  our  local  Ethics  Committee  and  all
patients  granted  their  informed  consent  to  participate  to  the
study.
Electrophysiological study
All  patients  received  effective  anticoagulation  therapy  (tar-
get  international  normalized  ratio  of  2.0—3.0)  for  ≥  1  month
before  procedure.  Oral  anticoagulation  was  stopped  2  days
before  the  procedure  and  low  molecular  weight  heparin
was  started.  The  electrophysiological  study  was  performed
under  conscious  sedation.  The  following  catheters  were
introduced  via  the  right  femoral  vein  for  electrophysio-
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ogical  study:  a  steerable  decapolar  catheter  (deﬂectable
ecapolar  catheter;  Biosense  Webster,  Diamond  Bar,  CA,
SA)  was  positioned  within  the  coronary  sinus;  a  circumfer-
ntial  mapping  catheter  (Lasso;  Biosense  Webster,  Diamond
ar,  CA,  USA)  was  introduced  into  the  left  atrium  (LA)
ollowing  transseptal  access  and  was  stabilized  using  a
ong  sheath  (SL0  sheath;  St.  Jude  Medical,  St.  Paul,  MN,
SA)  continuously  perfused  with  heparinized  saline;  and  a
.5  mm  externally  irrigated-tip  ablation  catheter  (Navistar
hermocool;  Biosense  Webster)  was  used  for  mapping  and
blation.
Following  transseptal  access,  a  single  bolus  of  100  IU/kg
ody  weight  of  heparin  was  administrated  and  repeated  to
aintain  an  activated  clotting  time  of  between  300  and
50  seconds.  Three-dimensional  geometry  of  the  LA  was
econstructed  with  the  CARTO  3  electroanatomical  mapping
ystem  (Biosense  Webster,  Diamond  Bar,  CA,  USA).
Surface  electrocardiograms  and  bipolar  endocardial
GMs  were  continuously  monitored  and  recorded  on  a
omputer-based  digital  ampliﬁer/recorder  system  for  off-
ine  analysis  (Bard  Electrophysiology,  Lowell,  MA,  USA).
ntracardiac  EGMs  were  ﬁltered  from  30  to  500  Hz  and  mea-
ured  at  a sweep  speed  of  100  mm/s.  AF  cycle  length  was
easured  5  minutes  after  sustained  AF  and  before  AF  ter-
ination  from  the  left  atrial  appendage,  averaged  over  a
inimum  of  10  cycles.  Radiofrequency  energy  was  delivered
ith  25—35  W  power  using  irrigation  rates  of  17—60  mL/min
0.9%  saline  via  Cool  Flow;  Biosense  Webster,  Diamond  Bar,
A,  USA),  with  temperature  limited  to  45 ◦C.
ulmonary vein isolation
lectrical  PVI  was  performed  in  all  patients  using  an  antral
blation  strategy  and  was  considered  successful  when  all
he  pulmonary  veins  were  isolated  electrically  as  assessed
y  entrance  block  using  the  Lasso  catheter,  with  a  waiting
ime  of  30  minutes.
lectrogram-guided ablation
f  AF  was  not  spontaneously/mechanically  induced,
ttempts  to  induce  AF  with  burst  pacing  and/or  isopro-
erenol  infusion  were  performed  in  all  remaining  patients.
dditional  EGM-based  ablation  was  performed  if  AF  was
ustained  for  >  10  minutes,  at  the  discretion  of  the  operator.
hen  performed,  EGM-guided  ablation  targeted  sites  of
ontinuous  electrical  activity,  high-frequency  complex
ractionated  activity,  locally  short  AF  cycle  length  (AFCL)
r  intermittent  local  burst  activity,  temporal  activation
radient  between  the  distal  and  proximal  bipoles  of  the
oving  ablation  catheter  and  local  spreading  of  centrifugal
ctivation  [13].  The  desired  procedural  endpoint  was
ermination  of  AF  and,  whenever  possible,  mapping  and
blation  of  subsequent  atrial  tachycardia  (AT),  aiming  at
chievement  of  SR  by  ablation  only.  Linear  ablation  was
nly  performed  in  cases  where  conversion  to  AT  with  a
acrore-entrant  mechanism  was  proven.  Linear  lesions
ere  created  with  the  aim  of  achieving  bidirectional
lock  [14]. If  AF  termination  was  not  achieved,  despite
limination  of  complex  fractionated  EGMs,  the  patient
as  externally  cardioverted.  The  ablation  technique  was
bsolutely  identical  in  both  centres.
5 F.A.  Sebag  et  al.
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Figure 1. Procedural ﬂowchart with ablation steps and numbers
of patients with PVI-only performed at the index procedure ver-
sus those who underwent PVI plus EGM-guided ablation. Results of
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ollow-up
atients  were  followed  every  3  months  with  systematic  12-
ead  electrocardiograms  and  4—7  day  Holter  monitoring  at
he  tertiary  centre  as  well  as  by  routine  follow-up  by
he  referring  cardiologist.  Antiarrhythmic  drug  treatment,
ncluding  amiodarone,  was  continued  for  1—3  months  after
he  procedure,  at  the  discretion  of  the  cardiologist.  Patients
ith  arrhythmia  recurrences  after  a  3-month  blanking  period
ere  offered  a  repeat  procedure.
epeat procedures
s  the  ﬁrst  step,  electrical  conduction  of  the  pulmonary
eins  was  assessed  using  a  circumferential  mapping  catheter
nd  reisolation  was  performed  when  necessary.  If  AF  per-
isted,  EGM-guided  ablation  was  performed  with  the  same
echniques  as  described  for  the  index  procedure,  at  the
iscretion  of  the  operator,  but  similarly  in  both  centres.
apping  and  ablation  of  AT  were  also  performed  using  the
echniques  described  above.
tatistical analysis
ontinuous  variables  are  expressed  as  means  ±  standard
eviations.  Statistical  signiﬁcance  was  assessed  using  the
npaired  Student’s  t  test  or  the  Mann-Whitney  test.  Cate-
orical  variables  are  expressed  as  numbers  or  percentages
nd  were  analysed  using  the  chi-square  test  or  Fisher’s  exact
est.  Arrhythmia  recurrences  are  reported  graphically  using
he  Kaplan-Meier  method;  the  log-rank  test  was  applied
or  the  time  to  event.  Follow-up  duration,  in  particular,
s  expressed  as  median  ±  interquartile  range.  A  univari-
te  analysis  of  variables  was  performed.  Univariate  factors
resenting  P  <  0.10  were  analysed  using  Cox  proportional
azards  models  (multivariable  analysis).  All  hypotheses  were
wo-tailed  and  P  <  0.05  was  considered  as  statistically  signif-
cant.
esults
tudy population
f  216  patients  referred  for  catheter  ablation  of  PsAF,
5  patients  (mean  age  60.1  ±  8.9  years;  81.5%  men)  met  the
nclusion  criteria.  The  mean  time  since  initial  diagnosis  of
F  was  43  ±  30  months.  Patient  baseline  characteristics  are
escribed  in  Table  1.
All  patients  underwent  PVI  and  pulmonary  veins  were
lectrically  isolated  in  64  patients  (98%);  a  right  infe-
ior  pulmonary  vein  remained  connected  in  one  patient.
F  was  initiated  during  the  procedure  in  60  patients
92%)  with  a  mean  AFCL  of  152.7  ±  15.6  ms,  (sponta-
eously/mechanically  in  50  patients  and  induced  by  pacing
r  isoproterenol  in  10  patients).  The  ‘PVI-only’  group  was
omposed  of  28  patients  who  did  not  have  further  ablation
espite  having  AF  plus  the  ﬁve  patients  who  did  not  have
nducible  AF.  Consequently,  EGM-guided  ablation  was  per-
ormed  in  32  patients  (49.2%),  the  ‘PVI-EGM’  group.  There
as  no  difference  in  baseline  AFCL  between  the  PVI-only
nd  PVI-EGM  groups  (151.8  ±  17.7  ms  vs.  153.6  ±  13.9  ms;
3
a
P
(rst and subsequent procedures are described in both groups. EGM:
lectrogram; PVI: pulmonary vein isolation.
 =  0.66,  respectively).  Details  of  ablation  steps  with  the
umbers  of  patients  at  each  step  are  presented  in  Fig.  1.
VI only versus PVI with EGM-guided ablation
atient  characteristics  of  the  two  groups  are  described  in
able  1. Patients  with  and  without  EGM-guided  ablation
dded  to  PVI  had  similar  baseline  characteristics  and  demo-
raphics,  time  since  initial  presentation  with  AF,  duration  of
sAF  and  LA  dimensions.  The  rates  of  patients  included  in
he  PVI-only  group  were  similar  in  both  centres  (52%  vs.  50%;
 =  0.95).
Patients  undergoing  EGM-guided  ablation  had  signiﬁ-
antly  more  ATs  during  the  index  procedure  (31.2%  vs.
.0%;  P  =  0.002),  more  roof  lines  (31%  vs.  0%;  P  =  0.0003)
nd/or  more  mitral-isthmus  lines  performed  (15.6%  vs.  0%,
 =  0.02)  and  longer  radiofrequency  and  procedure  times
82.5  ±  13.3  minutes  vs.  54.6  ±  23.2  minutes;  P  <  0.0001  and
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Table  1  Baseline  characteristics  of  overall  population  and  univariate  analysis  of  characteristics  of  patients  with  or
without  electrogram-guided  ablation  added  to  pulmonary  vein  isolation.
Overall
(n  =  65)
PVI  only
(n =  33)
PVI-EGM
(n  =  32)
P
Demographics
Age  (years)  60.1  ±  8.9  59.5  ±  9.3  60.7  ±  8.5  0.59
Men  53  (81.5)  27  (81.8)  26  (81.2)  0.95
Henri-Mondor  Hospital  patients 34  (52.3) 18  (54.5) 16  (50.0)  0.95
Body  mass  index  (kg/m2) 26.7  ±  4.0 26.5  ±  4.7 26.8  ±  3.1 0.72
AF  description
AF history  (months) 43.6  ±  30.1 43.7  ±  30.6 43.4  ±  30.1 0.97
AF  duration  <  3  months  53  (81.5)  27  (81.8)  26  (81.2)  0.95
No.  of  previous  DCCVs  1.7  (1—5)  1.7  (1—5)  1.8  (1—5)  0.83
No.  of  failed  antiarrhythmic  drugs  2.2  ±  0.74  2.2  ±  0.8  2.1  ±  0.7  0.64
Amiodarone  25  (38.5)  12  (36.4)  13  (40.6)  0.72
Cardiac  history 16 (24.6) 9  (27.3) 7  (21.9) 0.61
Ischaemic  heart  disease 8  (12.3) 3  (9.1) 5  (15.6) 0.47
Dilated  cardiomyopathy  6  (9.2)  4  (12.1)  2  (6.2)  0.67
Hypertrophic  cardiomyopathy  1  (1.5)  1  (3.0)  0  (0.0)  1
Valvular  heart  disease  3  (4.6)  2  (6.1)  1  (3.1)  1
Congestive  heart  failure  4  (6.2)  2  (6.1)  2  (6.2)  1
Medical  history
Hypertension  27  (41.5)  14  (42.4)  13  (40.6)  0.88
Diabetes  6  (9.2)  3  (9.1)  3  (9.4)  1
Stroke  4  (6.2)  3  (9.1)  1  (3.1)  0.61
CHA2DS2-VASc  score  1.4  (0—6)  1.4  (0—5)  1.4  (0—6)  0.87
Smoking  9  (13.8)  4  (12.1)  5  (15.6)  0.73
Dyslipidaemia  9  (13.8)  4  (12.1)  5  (15.6)  0.73
Echocardiographic  measurements
LVEF  (%)  53.5  ±  10.1  54.0  ±  9.7  53.0  ±  10.7  0.69
LA  area  (cm2)  24.7  ±  4.1  24.7  ±  4.2  24.6  ±  4.1  0.94
LA  diameter  (mm)  43.5  ±  4.3  43.5  ±  4.3  43.4  ±  4.4  0.92
Procedural  data
AFCL  at  start  (ms)  152.7  ±  15.6  151.8  ±  17.7  153.6  ±  13.9  0.66
PVI  achieved  64  (98.5)  32  (97.0)  32  (100.0)  0.32
Time  to  PVI  (minutes)  38.8  ±  4.7  39.7  ±  4.7  37.8  ±  4.7  0.12
Atrial  tachycardia  11  (16.9)  1  (3.0)  10  (31.2)  0.002
Roof  line  10  (15.5)  0  (0.0)  10  (31.2)  0.0003
Mitral  line  5  (7.7)  0  (0.0)  5  (15.6)  0.02
Cavotricuspid  isthmus  line  7  (10.8)  2  (6.1)  5  (15.6)  0.25
AFCL  preconversion  (ms)  165.0  ±  19.1  156.4  ±  18.1  172.6  ±  16.6  0.0006
Radiofrequency  time  (minutes)  68.4  ±  23.5  54.6  ±  23.2  82.5  ±  13.3  <  0.0001
Procedure  time  (minutes)  187  ±  42.1  173.8  ±  42.5  202.4  ±  37.0  0.005
Data are mean ± standard deviation, mean (range) or number (%). AF: atrial ﬁbrillation; AFCL: atrial ﬁbrillation cycle length; DCCV:
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202.4  ±  37.0  minutes  vs.  173.8  ±  42.5  minutes;  P  =  0.005,
respectively)  compared  with  the  PVI-only  group.
Follow-up and predictors of outcome after the
index procedureThe  median  follow-up  was  18  ±  10  months.  Follow-up  dura-
tion  was  signiﬁcantly  longer  in  the  PVI-EGM  group  (20  ±  11
vs.  12  ±  4;  P  =  0.02).  As  shown  in  Fig.  2A,  in  our  cohort,
49  patients  (75%)  experienced  arrhythmia  recurrences  after
c
A
v
Pction fraction; PVI: pulmonary vein isolation.
he  index  procedure.  In  addition,  patients  in  the  PVI-only
roup  had  a  signiﬁcantly  higher  recurrence  rate  (82%)  com-
ared  with  patients  in  the  PVI-EGM  group  (69%;  P  =  0.047;
ig.  2B).  Among  them,  43  (88%)  and  six  (12%)  patients  had
ecurrences  of  AF  and  AT,  respectively.  The  characteristics
f  patients  with  or  without  recurrences  after  a  single  pro-
edure  are  described  in  Table  2. Of  the  43  patients  with
F  recurrences,  27  (63%)  were  in  the  PVI-only  group.  Con-
ersely,  all  the  patients  presenting  with  AT  were  in  the
VI-EGM  group.
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Figure 2. Kaplan-Meier analysis of time to recurrent arrhythmia after the index procedure for the overall population (A) and according
t ulatio
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r
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Fo index procedure strategy (B) for both groups, for the overall pop
trategy (D). AF: atrial ﬁbrillation; EGM: electrogram; PVI: pulmona
Finally,  the  independent  predictors  for  arrhythmia  recur-
ences  after  the  index  procedure  by  multiple  Cox  regression
Table  3)  were  the  presence  of  added  EGM-guided  abla-
ion  (P  <  0.001)  and  a  larger  LA  transverse  diameter
P  <  0.001).
m
R
an after the latest procedure (C) and according to index procedure
in isolation; SR: sinus rhythm.
ollow-up and predictors of outcome after
ultiple procedures
edo  procedures  were  performed  in  all  patients  with
rrhythmia  recurrences.  The  median  follow-up  after  the
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Table  2  Univariate  analysis  of  characteristics  of  patients  with  or  without  arrhythmia  recurrences  after  the  ﬁrst
procedure.
No  recurrences
(n =  16)
Recurrences
(n  =  49)
P
Demographic
Age  (years)  60.5  ±  8.5  60.0  ±  9.51  0.84
Men  12  (75.0)  41  (83.7)  0.47
Body  mass  index  (kg/m2) 26.4  ±  3.8 26.7  ±  4.1  0.74
AF  description
AF history  (months) 50.5  ±  31.1 41.3  ±  29.8 0.29
AF  duration  <  3  months 12  (75.0) 41  (83.7) 0.47
No.  of  previous  DCCVs  1.4  (1—3)  1.9  (1—5)  0.10
No.  of  failed  antiarrhythmic  drugs  2.0  ±  0.7  2.2  ±  0.7  0.30
Amiodarone  7  (43.8)  18  (36.7)  0.77
Cardiac  history
Ischaemic  heart  disease 0  (0.0) 8  (16.3)  0.18
Dilated  cardiomyopathy 0  (0.0) 6  (12.2) 0.32
Hypertrophic  cardiomyopathy 1  (6.2) 0  (0.0) 0.25
Valvular  heart  disease 0  (0.0) 3  (6.1) 0.57
Congestive  heart  failure 0  (0.0) 4  (8.2) 0.57
Medical  history
Hypertension  6  (37.5)  21  (42.9)  0.78
Diabetes  3  (18.8)  3  (6.1)  0.15
Stroke  0  (0.0)  4  (8.2)  0.56
CHA2DS2-VASc  score  1.3  (0—4)  1.4  (0—6)  0.78
Smoking  3  (18.8)  6  (12.2)  0.68
Dyslipidaemia  2  (12.5)  7  (14.3)  1
Echocardiographic  measurements
LVEF  (%)  60.0  ±  4.1  51.4  ±  10.6  0.003
LA  area  (cm2)  20.4  ±  1.6  26.0  ±  3.7  <  0.0001
LA  diameter  (mm)  38.9  ±  3.3  44.9  ±  3.6  <  0.0001
Procedural  data
Per  procedural  AF  (%)  12  (75.0)  48  (98.0)  0.01
AFCL  at  start  (ms)  151.5  ±  14.6  153.1  ±  16.0  0.76
AFCL  preconversion  (ms)  167.3  ±  20.5  164.5  ±  19.0  0.65
Time  to  PVI  (minutes)  38.4  ±  4.8  37.8  ±  4.8  0.72
Radiofrequency  time  (minutes)  71.8  ±  21.9  67.4  ±  24.1  0.58
Procedure  time  (minutes)  194.7  ±  51.5  185.7  ±  38.9  0.46
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direct current cardioversion; LA: left atrium; LVEF: left ventricula
latest  procedure  was  10  ±  3  months  and  was  similar  in  both
groups  (P  =  0.65).  All  patients  had  pulmonary  vein  reconnec-
tion.  A  mean  of  1.5  ±  1.2  pulmonary  veins  were  reconnected
when  checked  at  the  second  ablation  procedure.  Of  the
patients  who  initially  underwent  a  PVI-only  strategy  at  the
index  procedure,  21  (64%)  had  additional  EGM-guided  abla-
tion;  of  these,  17  had  linear  lesions.  A  further  four  patients
presenting  with  AT  had  linear  lesions  only  following  PVI.
Eventually,  38  (58%)  patients  were  in  stable  SR  after  mul-
tiple  procedures,  resulting  in  an  overall  success  rate  of  82%,
with  54  patients  in  SR  after  2.04  ±  0.80  procedures  and  a
median  follow-up  of  10  ±  3  months  after  the  latest  proce-
dure  (Fig.  2C).  Finally,  the  mean  number  of  procedures  was
signiﬁcantly  higher  in  the  PVI-only  group  (2.24  ±  0.75  vs.
1.84  ±  0.81;  P  =  0.04)  to  achieve  a  similar  outcome  compared
with  the  PVI-EGM  group  (84%  vs.  81%;  P  =  0.833;  Fig.  2D).
O
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i: atrial ﬁbrillation; AFCL: atrial ﬁbrillation cycle length; DCCV:
ction fraction; PVI: pulmonary vein isolation.
dverse events
ne  tamponade  was  seen  in  the  PVI-only  group,  success-
ully  treated  with  percutaneous  drainage.  Six  groin-related
omplications  were  seen,  one  requiring  surgical  repair.  No
ulmonary  vein  stenoses,  strokes,  blood  transfusions  or
sophageal  ﬁstulae  occurred.
iscussion
ajor ﬁndingur  major  ﬁnding  is  that  complementary  ablation,  mainly
ith  EGM-guided  ablation,  in  patients  with  PsAF  presenting
n  SR  the  day  of  the  procedure,  results  in  fewer  procedures
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Table  3  Cox  model  analysis  (multivariable  analysis)  of
factors  associated  with  arrhythmia  recurrences  after  the
index  procedure.
P  OR  95%  CI
Per  procedural  AF  0.37  2.61  0.31—21.55
LVEF  0.82  1.00  0.95—1.06
LA  area  0.42  1.06  0.92—1.23
LA  diameter <  0.001 1.79 1.44—2.23
Type  of  procedure:
PVI  +  EGM
< 0.001 0.23 0.12—0.45
AF: atrial ﬁbrillation; CI: conﬁdence interval; EGM: electro-
gram; LA: left atrium; LVEF: left ventricular ejection fraction;
t
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gest  that  while  electrical  remodelling  with  SR  favourablyOR: odds ratio; PVI: pulmonary vein isolation.
o  maintain  SR  in  the  mid-term  follow-up  compared  with  a
VI  only  strategy.
eﬁnition of atrial ﬁbrillation
 simple  and  clinically  relevant  consensus  classiﬁcation
cknowledges  three  patterns  of  recurrent  AF  for  which
atheter  ablation  is  a  recognized  treatment  modality:  parox-
smal  (lasting  <  7  days  and  self-terminating);  persistent
lasting  >  7  days  and  requiring  electrical  or  pharmacological
ardioversion);  and  long-standing  PsAF  [9].  The  accuracy  and
eliability  of  this  classiﬁcation  are  not  clearly  related  to  any
peciﬁc  pathophysiology  or  mechanism  of  arrhythmogene-
is.  As  a  consequence,  investigators  have  tried  to  establish
urther  reﬁnements  based  on  co-morbidities  [15,16],  symp-
oms  [17]  and  substrate  impairment  [18].  Patients  with
sAF  are  a  more  heterogeneous  group  compared  with  PAF,
s  shown  by  the  wide  variability  of  patient  demograph-
cs,  presence  of  underlying  cardiac  disease  [19],  ablation
echniques  and  outcome  [11].  We  hypothesized  that  one
f  the  major  reasons  for  the  variability  of  outcome  in
atients  with  PsAF  is  the  degree  of  atrial  remodelling  asso-
iated  with  a  varying  burden  of  AF  [20].  In  our  study,
e  identiﬁed  patients  who  were  in  the  transition  zone
etween  PAF  and  PsAF  as  presenting  in  SR  on  the  day  of
he  procedure  and  having  periods  of  SR  between  AF  of
 months.
he transition between paroxysmal and
ersistent atrial ﬁbrillation
ur  study  demonstrates  that  patients  in  the  early  stage  of
sAF  have  mixed  characteristics  of  PAF  and  PsAF.  Indeed,  our
opulation  has  few  co-morbidities  or  underlying  cardiac  dis-
ase,  characteristics  that  are  more  often  seen  in  patients
ith  PAF  [3,5,8].  In  agreement  with  previous  reports,  the
FCL  was  relatively  long  for  all  patients  with  PsAF  (153  ms),
nd  this  has  been  shown  to  correlate  with  AF  termination
y  catheter  ablation  [21].  These  observations  support  the
otion  of  a  less-advanced  atrial  substrate  in  this  group  and
ould  explain  the  favourable  outcome  of  patients  in  our
tudy  compared  with  a  broad  population  of  patients  with
sAF.  In  our  study,  the  overall  success  rate  was  82%,  which
s  similar  to  previous  results  published  in  the  literature
a
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oncerning  PsAF  ablation  [4,22]  and  PAF  ablation  [3,5].  How-
ver,  the  total  number  of  procedures  required  to  achieve  this
utcome  is  higher  than  in  patients  with  PAF  [3,5]  and  more
omparable  to  those  with  PsAF  [23].  Rather  than  advocat-
ng  a  PVI-only  approach  for  early  persistent  AF,  therefore,
he  data  argue  for  a  more  aggressive  index  procedure  to
chieve  the  best  clinical  outcome  at  the  lowest  procedural
ost.
eterogeneity within persistent atrial
brillation patients
here  is  considerable  debate  regarding  the  ideal  ablation
trategy  for  patients  with  PAF.  In  our  study,  half  of  the
atients  had  PVI  only,  the  gold-standard  ablation  strategy
or  PAF,  and  the  minimum  for  PsAF  [9]. Studies  investigating
he  efﬁcacy  of  PVI  only  in  PsAF  revealed  a  single-procedure
utcome  ranging  from  40%  to  68%  [4,24—26].  Within  these
tudies,  however,  there  is  considerable  variation  in  the
atient  population,  with  mean  age,  LA  diameter  and  ejec-
ion  fraction  ranging  from  50  to  59  years,  41  to  47  mm  and
2%  to  63%,  respectively.  However,  these  former  studies
ncluded  patients  with  AF  duration,  LA  size  and  ejection
raction  similar  to  a  PAF  population.  In  contrast  to  those  ﬁnd-
ngs,  the  present  study  compared  two  distinct  and  widely
racticed  ablation  strategies  in  a  more  uniform  cohort  of
arly  PsAF  patients.  A  PVI-only  strategy  is  clearly  less  effec-
ive  than  a  PVI-EGM  approach  when  the  total  number  of
rocedures  performed  is  taken  into  account,  suggesting
hat  our  current  clinical  tools  for  deciding  upon  ablation
trategy  are  ﬂawed  and  underestimate  the  pathophysiolog-
cal  state  of  the  atrium  in  early  PsAF  [27].  Nonetheless,
on-inducibility  of  AF  following  PVI  only  is  a good  marker
or  single  procedure  clinical  success  in  this  cohort  of
atients.
lectrical remodelling
n  a  landmark  animal  study,  Wijffels  et  al.  demonstrated  that
aintenance  of  AF  led  to  sustained  AF  within  2—3  weeks.
nterestingly,  electrical  remodelling  reversed  almost  com-
letely  within  1  week  of  sustained  SR  and  completely
fter  2  weeks,  with  the  refractory  periods,  AFCLs  and  AF
nducibility  returning  to  baseline  levels  [28].  Recently,
ivard  et  al.  demonstrated  that  cardioversion  and  main-
enance  of  SR  for  at  least  1  month  before  ablation  for
sAF  decreases  the  extent  of  ablation  to  achieve  SR
29], in  support  of  a  reversible  component  to  the  atrial
ubstrate  in  human  PsAF.  In  the  present  study,  the  main-
enance  of  SR  in  this  selected  population  of  patients  with
arly  PsAF  led  individual  operators  to  treat  these  patients
ith  PVI  only,  to  try  to  prevent  iatrogenic  ATs  and  the
omplications  seen  with  more  extensive  ablation  strate-
ies.  Despite  being  in  SR  at  the  time  of  ablation,  however,
hese  patients  had  a higher  recurrence  rate  than  expected
or  a  PAF  population  and  required  more  procedures  than
hose  patients  treated  with  additional  substrate  ablation
t  the  index  procedure.  These  data  taken  together  sug-ffects  the  atrial  substrate,  once  patients  have  transi-
ioned  to  PsAF,  some  substrate  modiﬁcation  beyond  PVI  is
equired.
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Study limitations
This  was  a  retrospective  two-centre  study  that  needs  to  be
conﬁrmed  prospectively  with  a  larger  population  of  patients.
Despite,  the  lack  of  randomization,  there  was  no  baseline
difference  between  the  PVI-only  and  PVI-EGM  groups,  espe-
cially  regarding  the  centre  origin  of  patients.  Moreover,
even  if  the  type  of  substrate  ablation  was  not  standard-
ized  within  centres  and  between  centres,  the  technique
used  to  achieve  this  substrate  modiﬁcation  was  uniform
within  both  centres  and  operators.  In  addition,  some  PVI-
only  patients  required  further  substrate  ablation  during
the  subsequent  procedures.  However,  we  believe  that  this
observation  should  not  be  associated  with  important  bias
as  this  was  a  cohort  retrospective  non-randomized  trial.
A  precise  estimate  of  AF  burden  was  not  documented  by
daily  transtelephonic  monitoring.  However,  more  than  80%
of  our  patients  had  a  persistent  AF  duration  of  > 3  months,
emphasizing  the  concept  of  ‘early  persistent  AF’.  In  addi-
tion,  the  patients  were  highly  symptomatic  and  so  following
a  cardioversion  it  is  unlikely  that  they  had  a  sustained  recur-
rence  of  AF  but  intervening  periods  of  asymptomatic  AF  may
have  occurred.  Due  to  the  retrospective  design  of  this  study,
follow-up  duration  after  the  index  procedure  was  signiﬁcan-
tly  higher  in  the  PVI-EGM  group.  However,  the  recurrence
rate  was  higher  in  the  group  in  which  follow-up  duration
was  the  shortest.  Although  the  overall  follow-up  was  rela-
tively  long  (18  ±  10  months),  the  median  follow-up  after  the
ﬁnal  procedure  was  only  10  months  and  could  have  overes-
timated  the  success  rate  of  our  procedures.  Patients  were
not  monitored  intensively  following  their  DCCV  or  for  the
month  preceding  the  ablation  and  so  intervening  periods
of  asymptomatic  AF  may  have  occurred.  There  is  a  trend,
although  non-signiﬁcant,  towards  a  higher  time  to  achieve
PVI  in  the  PVI-only  group.  Therefore,  PVI-EGM  group  selec-
tion  could  have  been  skewed  towards  a  more  extensive  PVI
procedure.  However,  time  taken  to  perform  PVI  has  not  been
demonstrated  to  be  a  predictive  factor  for  recurrence  in  this
cohort.
Conclusions
In  patients  presenting  at  the  early  stage  of  PsAF  and  in  SR
during  the  index  AF  ablation  procedure,  a  PVI  with  EGM-
guided  ablation  approach  had  the  highest  ability  to  maintain
SR  after  a  single  procedure  and  requires  fewer  procedures
to  achieve  a  similar  clinical  efﬁcacy  in  the  short-  to  medium-
term  follow-up  compared  with  a  PVI-only  strategy.
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